Direction, evidence grade, and study type are AI-generated labels (gpt-5-mini), not human-verified. Syntheses are LLM-written. "Tensions" are machine-detected candidates, not confirmed contradictions. A research-acceleration tool, not peer review.
How this is built →
1Distinct papers
2Unique collaborators
1/1OpenAlex citation coverage
Publication dates unavailable. Corpus fetch span: 2026.
Identity provenance
Provider IDs
- Openalex:
A5121201524
ORCID evidence
No valid ORCID is stored.
Observed aliases (1)
- Célia Fortuna Rodrigues (openalex, provider refresh)
Topics and outcomes in this view
Assessment themes
- Adoption: 1 paper
- Governance: 1 paper
- Innovation: 1 paper
- Productivity: 1 paper
- Skills Training: 1 paper
Claim outcomes
- Firm Productivity: 1 paper
- Governance And Regulation: 1 paper
- Market Structure: 1 paper
- Output Quality: 1 paper
- Research Productivity: 1 paper
- Adoption Rate: 1 paper
- Ai Safety And Ethics: 1 paper
- Error Rate: 1 paper
- Hiring: 1 paper
- Inequality: 1 paper
- Organizational Efficiency: 1 paper
- Regulatory Compliance: 1 paper
- Task Completion Time: 1 paper
Papers in the OpenAlex view
Latest stored OpenAlex author observations only. Citation counts below are from the same provider and are not combined with other services.
Scroll the table horizontally to see every column.
| Paper | Author evidence | Date | Provider citations |
|---|---|---|---|
| AI is speeding up drug discovery and clinical development—cutting timelines and reducing some failure modes—but the economic upside will accrue unevenly because performance depends on proprietary data, heavy upfront costs and regulatory uncertainty.semantic_scholar | Célia Fortuna Rodrigues provider id |
Fetched 2026-03-18 | 2 |
Citation observation summary
OpenAlex supplied counts for 1 of 1 papers in this view; 0 are missing. The observed paper counts sum to 2 cumulative citations. This is a coverage summary, not an author score or h-index.